Related references
Note: Only part of the references are listed.Comprehensive genetic features of gastric mixed adenoneuroendocrine carcinomas and pure neuroendocrine carcinomas
Jiwon Koh et al.
JOURNAL OF PATHOLOGY (2021)
Capecitabine-Temozolomide in Advanced Grade 2 and Grade 3 Neuroendocrine Neoplasms: Benefits of Chemotherapy in Neuroendocrine Neoplasms with Significant 18FDG Uptake
Vikas Ostwal et al.
NEUROENDOCRINOLOGY (2021)
Genomics of High-Grade Neuroendocrine Neoplasms: Well-Differentiated Neuroendocrine Tumor with High-Grade Features (G3 NET) and Neuroendocrine Carcinomas (NEC) of Various Anatomic Sites
Silvia Uccella et al.
ENDOCRINE PATHOLOGY (2021)
Temozolomide Alone or Combined with Capecitabine for the Treatment of Advanced Pancreatic Neuroendocrine Tumor
Louis de Mestier et al.
NEUROENDOCRINOLOGY (2020)
Pancreatic High-Grade Neuroendocrine Neoplasms in the Korean Population: A Multicenter Study
Haeryoung Kim et al.
CANCER RESEARCH AND TREATMENT (2020)
The 2019 WHO classification of tumours of the digestive system
Iris D. Nagtegaal et al.
HISTOPATHOLOGY (2020)
Grade is a Dominant Risk Factor for Metastasis in Patients with Rectal Neuroendocrine Tumors
Ian W. Folkert et al.
ANNALS OF SURGICAL ONCOLOGY (2020)
High-Grade Progression Confers Poor Survival in Pancreatic Neuroendocrine Tumors
Johan Botling et al.
NEUROENDOCRINOLOGY (2020)
Efficacy and Safety of Pembrolizumab in Previously Treated Advanced Neuroendocrine Tumors: Results From the Phase II KEYNOTE-158 Study
Jonathan Strosberg et al.
CLINICAL CANCER RESEARCH (2020)
PRRT in high-grade gastroenteropancreatic neuroendocrine neoplasms (WHO G3)
Halfdan Sorbye et al.
ENDOCRINE-RELATED CANCER (2020)
Predictors of Recurrence and Survival in Patients With Surgically Resected Pancreatic Neuroendocrine Tumors
Rachel E. Rosenblum et al.
PANCREAS (2020)
Pancreatic grade 3 neuroendocrine tumors behave similarly to neuroendocrine carcinomas following resection: a multi-center, international appraisal of the WHO 2010 and WHO 2017 staging schema for pancreatic neuroendocrine lesions
Patrick J. Worth et al.
HPB (2020)
Outcomes of Capecitabine and Temozolomide (CAPTEM) in Advanced Neuroendocrine Neoplasms (NENs)
Katharine Thomas et al.
CANCERS (2020)
Grade 3 Pancreatic Neuroendocrine Tumors on MDCT: Establishing a Diagnostic Model and Comparing Survival Against Pancreatic Ductal Adenocarcinoma
Hai-Yan Chen et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2020)
Gastroenteropancreatic neuroendocrine neoplasms: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up y
M. Pavel et al.
ANNALS OF ONCOLOGY (2020)
Pembrolizumab monotherapy in patients with previously treated metastatic high-grade neuroendocrine neoplasms: joint analysis of two prospective, non-randomised trials
Namrata Vijayvergia et al.
BRITISH JOURNAL OF CANCER (2020)
Prognostic Value of 18F-FDG PET/CT in a Large Cohort of Patients with Advanced Metastatic Neuroendocrine Neoplasms Treated with Peptide Receptor Radionuclide Therapy
Jingjing Zhang et al.
JOURNAL OF NUCLEAR MEDICINE (2020)
Could pancreatic grade 3 neuroendocrine tumors really behave similarly to neuroendocrine carcinomas following resection?
Louis de Mestier et al.
HPB (2020)
Well Differentiated Grade 3 Neuroendocrine Tumors of the Digestive Tract: A Narrative Review
Anna Pellat et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Morphological imaging and CT histogram analysis to differentiate pancreatic neuroendocrine tumor grade 3 from neuroendocrine carcinoma
A. Azoulay et al.
DIAGNOSTIC AND INTERVENTIONAL IMAGING (2020)
Candidate protein biomarkers in pancreatic neuroendocrine neoplasms grade 3
Abir Salwa Ali et al.
Scientific Reports (2020)
CT and MRI of pancreatic tumors: an update in the era of radiomics
Marion Bartoli et al.
JAPANESE JOURNAL OF RADIOLOGY (2020)
Surufatinib in advanced extrapancreatic neuroendocrine tumours (SANET-ep): a randomised, double-blind, placebo-controlled, phase 3 study
Jianming Xu et al.
LANCET ONCOLOGY (2020)
Grading of pancreatic neuroendocrine tumors on endoscopic ultrasound-guided fine-needle aspiration using Ki-67 index and 2017 World Health Organization criteria: An analysis of 32 cases
Sweety Kalantri et al.
CYTOJOURNAL (2020)
Advances in Molecular Imaging and Radionuclide Therapy of Neuroendocrine Tumors
Anna Yordanova et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Concordance Between the Ki-67 Index Cutoff Value of 55% and Differentiation in Neuroendocrine Tumor and Neuroendocrine Carcinoma in Grade 3 Pancreatic Neuroendocrine Neoplasms
Huiying Shi et al.
PANCREAS (2020)
Peptide receptor radionuclide therapy in gastroenteropancreatic NEN G3: a multicenter cohort study
Esben Andreas Carlsen et al.
ENDOCRINE-RELATED CANCER (2019)
Evaluating the Role of Theranostics in Grade 3 Neuroendocrine Neoplasms
Najeff Waseem et al.
JOURNAL OF NUCLEAR MEDICINE (2019)
CAPTEM in Metastatic Well-Differentiated Intermediate to High Grade Neuroendocrine Tumors: A Single Centre Experience
Arvind Sahu et al.
JOURNAL OF ONCOLOGY (2019)
Well-differentiated grade 3 neuroendocrine tumours and poorly differentiated grade 3 neuroendocrine carcinomas: will dual tracer PET-computed tomography (68Ga-DOTATATE and FDG) play a pivotal role in differentiation and guiding management strategies?
Sandip Basu et al.
NUCLEAR MEDICINE COMMUNICATIONS (2019)
Phase I Trial of Well-Differentiated Neuroendocrine Tumors (NETs) with Radiolabeled Somatostatin Antagonist 177Lu-Satoreotide Tetraxetan
Diane Reidy-Lagunes et al.
CLINICAL CANCER RESEARCH (2019)
Correlation of DOTATOC Uptake and Pathologic Grade in Neuroendocrine Tumors
Hilary Chan et al.
PANCREAS (2019)
Textural analysis on contrast-enhanced CT in pancreatic neuroendocrine neoplasms: association with WHO grade
Chuangen Guo et al.
ABDOMINAL RADIOLOGY (2019)
Deep lessons learned: Radiology, oncology, pathology, and computer science experts unite around artificial intelligence to strive for earlier pancreatic cancer diagnosis
E.M. Weisberg et al.
Diagnostic and Interventional Imaging (2019)
Unmet Needs in Functional and Nonfunctional Pancreatic Neuroendocrine Neoplasms
Robert T. Jensen et al.
NEUROENDOCRINOLOGY (2019)
Genomic characterization of a well-differentiated grade 3 pancreatic neuroendocrine tumor
Laura M. Williamson et al.
COLD SPRING HARBOR MOLECULAR CASE STUDIES (2019)
A Nationwide Population-Based Study on the Survival of Patients with Pancreatic Neuroendocrine Tumors in The Netherlands
C. G. Genc et al.
WORLD JOURNAL OF SURGERY (2018)
Combined test of serum CgA and NSE improved the power of prognosis prediction of NF-pNETs
Yang Lv et al.
ENDOCRINE CONNECTIONS (2018)
Prediction of Pancreatic Neuroendocrine Tumor Grade Based on CT Features and Texture Analysis
Rodrigo Canellas et al.
AMERICAN JOURNAL OF ROENTGENOLOGY (2018)
Well differentiated grade 3 pancreatic neuroendocrine tumors compared with related neoplasms: A morphologic study
Carlie S. Sigel et al.
CANCER CYTOPATHOLOGY (2018)
Clinical and Prognostic Value of PET/CT Imaging with Combination of Ga-68-DOTATATE and F-18-FDG in Gastroenteropancreatic Neuroendocrine Neoplasms
Panpan Zhang et al.
CONTRAST MEDIA & MOLECULAR IMAGING (2018)
The Problem of High-Grade Gastroenteropancreatic Neuroendocrine Neoplasms Well-Differentiated Neuroendocrine Tumors, Neuroendocrine Carcinomas, and Beyond
Halfdan Sorbye et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2018)
Clinical and Biomarker Evaluations of Sunitinib in Patients with Grade 3 Digestive Neuroendocrine Neoplasms
Anna Pellat et al.
NEUROENDOCRINOLOGY (2018)
Immune Checkpoint Inhibitors in the Treatment of Patients with Neuroendocrine Neoplasia
Matthias M. Weber et al.
ONCOLOGY RESEARCH AND TREATMENT (2018)
A randomized study of temozolomide or temozolomide and capecitabine in patients with advanced pancreatic neuroendocrine tumors: A trial of the ECOG-ACRIN Cancer Research Group (E2211).
Pamela L. Kunz et al.
JOURNAL OF CLINICAL ONCOLOGY (2018)
A common classification framework for neuroendocrine neoplasms: an International Agency for Research on Cancer (IARC) and World Health Organization (WHO) expert consensus proposal
Guido Rindi et al.
MODERN PATHOLOGY (2018)
Safety and efficacy of combining capecitabine and temozolomide (CAPTEM) to treat advanced neuroendocrine neoplasms A meta-analysis
Yaoheng Lu et al.
MEDICINE (2018)
Pancreatic neuroendocrine tumor: prediction of the tumor grade using CT findings and computerized texture analysis
Tae Won Choi et al.
ACTA RADIOLOGICA (2018)
Molecular characterization of metastatic pancreatic neuroendocrine tumors (PNETs) using whole-genome and transcriptome sequencing
Hui-li Wong et al.
COLD SPRING HARBOR MOLECULAR CASE STUDIES (2018)
The Clinicopathologic Heterogeneity of Grade 3 Gastroenteropancreatic Neuroendocrine Neoplasms: Morphological Differentiation and Proliferation Identify Different Prognostic Categories
Massimo Milione et al.
NEUROENDOCRINOLOGY (2017)
Professional Practices and Diagnostic Issues in Neuroendocrine Tumour Pathology: Results of a Prospective One-Year Survey among French Pathologists (the PRONET Study)
Jean-Yves Scoazec et al.
NEUROENDOCRINOLOGY (2017)
Poorly differentiated gastro-entero-pancreatic neuroendocrine carcinomas: Are they really heterogeneous? Insights from the FFCD-GTE national cohort
T. Walter et al.
EUROPEAN JOURNAL OF CANCER (2017)
Evaluation of 68Ga-DOTATOC PET/MRI for whole-body staging of neuroendocrine tumours in comparison with 68Ga-DOTATOC PET/CT
Lino M. Sawicki et al.
EUROPEAN RADIOLOGY (2017)
Whole-genome landscape of pancreatic neuroendocrine tumours
Aldo Scarpa et al.
NATURE (2017)
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Biochemical Markers
Kjell Oberg et al.
NEUROENDOCRINOLOGY (2017)
ENETS Consensus Guidelines for the Standards of Care in Neuroendocrine Tumors: Pathology-Diagnosis and Prognostic Stratification
Aurel Perren et al.
NEUROENDOCRINOLOGY (2017)
Phase 3 Trial of 177Lu-Dotatate for Midgut Neuroendocrine Tumors
J. Strosberg et al.
NEW ENGLAND JOURNAL OF MEDICINE (2017)
Treatment Response and Outcomes of Grade 3 Pancreatic Neuroendocrine Neoplasms Based on Morphology Well Differentiated Versus Poorly Differentiated
Nitya Raj et al.
PANCREAS (2017)
Everolimus in Pancreatic Neuroendocrine Carcinomas G3
Francesco Panzuto et al.
PANCREAS (2017)
The NETPET Score: Combining FDG and Somatostatin Receptor Imaging for Optimal Management of Patients with Metastatic Well-Differentiated Neuroendocrine Tumors
Elif Hindie
THERANOSTICS (2017)
Dual Somatostatin Receptor/FDG PET/CT Imaging in Metastatic Neuroendocrine Tumours: Proposal for a Novel Grading Scheme with Prognostic Significance
David L. H. Chan et al.
THERANOSTICS (2017)
Imaging of Chemokine Receptor 4 Expression in Neuroendocrine Tumors - a Triple Tracer Comparative Approach
Rudolf A. Werner et al.
THERANOSTICS (2017)
Neuroendocrine Neoplasms: Dichotomy, Origin and Classifications
Guenter Kloeppel
VISCERAL MEDICINE (2017)
Increased incidence trend of low-grade and high-grade neuroendocrine neoplasms
Emanuele Leoncini et al.
ENDOCRINE (2017)
Long-Term Efficacy, Survival, and Safety of [177Lu-DOTA0, Tyr3] octreotate in Patients with Gastroenteropancreatic and Bronchial Neuroendocrine Tumors
Tessa Brabander et al.
CLINICAL CANCER RESEARCH (2017)
Rb Loss and KRAS Mutation Are Predictors of the Response to Platinum-Based Chemotherapy in Pancreatic Neuroendocrine Neoplasm with Grade 3: A Japanese Multicenter Pancreatic NEN-G3 Study
Susumu Hijioka et al.
CLINICAL CANCER RESEARCH (2017)
Well-Differentiated Neuroendocrine Tumors with a Morphologically Apparent High-Grade Component: A Pathway Distinct from Poorly Differentiated Neuroendocrine Carcinomas
Laura H. Tang et al.
CLINICAL CANCER RESEARCH (2016)
A Practical Approach to the Classification of WHO Grade 3 (G3) Well-differentiated Neuroendocrine Tumor (WD-NET) and Poorly Differentiated Neuroendocrine Carcinoma (PD-NEC) of the Pancreas
Laura H. Tang et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2016)
Therapeutic management of poorly differentiated neuroendocrine lung tumors and neuroendocrine carcinomas of the digestive system
Anna Pellat et al.
BULLETIN DU CANCER (2016)
Heterogeneity of grade 3 gastroenteropancreatic neuroendocrine carcinomas: New insights and treatment implications
Nicola Fazio et al.
CANCER TREATMENT REVIEWS (2016)
Everolimus for the treatment of advanced, non-functional neuroendocrine tumours of the lung or gastrointestinal tract (RADIANT-4): a randomised, placebo-controlled, phase 3 study
James C. Yao et al.
LANCET (2016)
Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial
Howard L. Kaufman et al.
LANCET ONCOLOGY (2016)
ENETS Consensus Guidelines for High-Grade Gastroenteropancreatic Neuroendocrine Tumors and Neuroendocrine Carcinomas
R. Garcia-Carbonero et al.
NEUROENDOCRINOLOGY (2016)
ENETS 2016 Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Tumors: An Update
Dermot O'Toole et al.
NEUROENDOCRINOLOGY (2016)
PD-1 Blockade with Pembrolizumab in Advanced Merkel-Cell Carcinoma
Paul T. Nghiem et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Gastroenteropancreatic Well-Differentiated Grade 3 Neuroendocrine Tumors: Review and Position Statement
Romain Coriat et al.
ONCOLOGIST (2016)
The High-grade (WHO G3) Pancreatic Neuroendocrine Tumor Category Is Morphologically and Biologically Heterogenous and Includes Both Well Differentiated and Poorly Differentiated Neoplasms
Olca Basturk et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2015)
Gemcitabine and Oxaliplatin or Alkylating Agents for Neuroendocrine Tumors: Comparison of Efficacy and Search for Predictive Factors Guiding Treatment Choice
Anne-Sophie Dussol et al.
CANCER (2015)
Post-first-line FOLFOX chemotherapy for grade 3 neuroendocrine carcinoma
J. Hadoux et al.
ENDOCRINE-RELATED CANCER (2015)
Characteristics and treatment of patients with G3 gastroenteropancreatic neuroendocrine neoplasms
M. Heetfeld et al.
ENDOCRINE-RELATED CANCER (2015)
Calculation of the Ki67 index in pancreatic neuroendocrine tumors: a comparative analysis of four counting methodologies
Michelle D. Reid et al.
MODERN PATHOLOGY (2015)
GEP-NETS UPDATE Interventional radiology: role in the treatment of liver metastases from GEP-NETs
Thierry de Baere et al.
EUROPEAN JOURNAL OF ENDOCRINOLOGY (2015)
Gastroenteropancreatic High-Grade Neuroendocrine Carcinoma
Halfdan Sorbye et al.
CANCER (2014)
Pancreatic neuroendocrine tumour grading on endoscopic ultrasound-guided fine needle aspiration: high reproducibility and inter-observer agreement of the Ki-67 labelling index
B. Weynand et al.
CYTOPATHOLOGY (2014)
Bevacizumab combined with 5-FU/streptozocin in patients with progressive metastatic well-differentiated pancreatic endocrine tumours (BETTER trial) - A phase II non-randomised trial
Michel Ducreux et al.
EUROPEAN JOURNAL OF CANCER (2014)
Bevacizumab plus capecitabine in patients with progressive advanced well-differentiated neuroendocrine tumors of the gastro-intestinal (GI-NETs) tract (BETTER trial) - A phase II non-randomised trial
Emmanuel Mitry et al.
EUROPEAN JOURNAL OF CANCER (2014)
High Prognostic Value of 18F-FDG PET for Metastatic Gastroenteropancreatic Neuro endocrine Tumors: A Long-Term Evaluation
Haifa Bahri et al.
JOURNAL OF NUCLEAR MEDICINE (2014)
Reliability of Proliferation Assessment by Ki-67 Expression in Neuroendocrine Neoplasms: Eyeballing or Image Analysis?
Marie-Louise F. van Velthuysen et al.
NEUROENDOCRINOLOGY (2014)
Lanreotide in Metastatic Enteropancreatic Neuroendocrine Tumors
Martyn E. Caplin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): The NORDIC NEC study
H. Sorbye et al.
ANNALS OF ONCOLOGY (2013)
Are G3 ENETS neuroendocrine neoplasms heterogeneous?
Fritz-Line Velayoudom-Cephise et al.
ENDOCRINE-RELATED CANCER (2013)
Incidence and survival of neuroendocrine tumours in the Netherlands according to histological grade: Experience of two decades of cancer registry
Catharina M. Korse et al.
EUROPEAN JOURNAL OF CANCER (2013)
Small Cell and Large Cell Neuroendocrine Carcinomas of the Pancreas are Genetically Similar and Distinct From Well-differentiated Pancreatic Neuroendocrine Tumors
Shinichi Yachida et al.
AMERICAN JOURNAL OF SURGICAL PATHOLOGY (2012)
Pancreatic neuroendocrine tumors: Clinical features, diagnosis and medical treatment: Advances
Tetsuhide Ito et al.
BEST PRACTICE & RESEARCH CLINICAL GASTROENTEROLOGY (2012)
FOLFIRI regimen: an effective second-line chemotherapy after failure of etoposide-platinum combination in patients with neuroendocrine carcinomas grade 3
O. Hentic et al.
ENDOCRINE-RELATED CANCER (2012)
Choice of tumour markers in patients with neuroendocrine tumours is dependent on the histological grade. A marker study of Chromogranin A, Neuron specific enolase, Progastrin-releasing peptide and cytokeratin fragments
Catharina M. Korse et al.
EUROPEAN JOURNAL OF CANCER (2012)
Feasibility and Efficacy of Combined Cisplatin and Irinotecan Chemotherapy for Poorly Differentiated Neuroendocrine Carcinomas
Kenji Nakano et al.
JAPANESE JOURNAL OF CLINICAL ONCOLOGY (2012)
ENETS Consensus Guidelines for the Management of Patients with Digestive Neuroendocrine Neoplasms of the Digestive System: Well-Differentiated Pancreatic Non-Functioning Tumors
Massimo Falconi et al.
NEUROENDOCRINOLOGY (2012)
ENETS Consensus Guidelines for the Management of Patients with Neuroendocrine Neoplasms from the Jejuno-Ileum and the Appendix Including Goblet Cell Carcinomas
Ulrich-Frank Pape et al.
NEUROENDOCRINOLOGY (2012)
ENETS Consensus Guidelines for the Management of Patients with Liver and Other Distant Metastases from Neuroendocrine Neoplasms of Foregut, Midgut, Hindgut, and Unknown Primary
Marianne Pavel et al.
NEUROENDOCRINOLOGY (2012)
Liver-directed therapies in liver metastases from neuroendocrine tumors of the gastrointestinal tract
Magaly Zappa et al.
TARGETED ONCOLOGY (2012)
First-Line Chemotherapy With Capecitabine and Temozolomide in Patients With Metastatic Pancreatic Endocrine Carcinomas
Jonathan R. Strosberg et al.
CANCER (2011)
Clinical Effect of Temozolomide-Based Chemotherapy in Poorly Differentiated Endocrine Carcinoma After Progression on First-Line Chemotherapy
Staffan Welin et al.
CANCER (2011)
Phase II study of first-line FOLFIRI for progressive metastatic well-differentiated pancreatic endocrine carcinoma
Hedia Brixi-Benmansour et al.
DIGESTIVE AND LIVER DISEASE (2011)
The Epidemiology of Gastroenteropancreatic Neuroendocrine Tumors
Ben Lawrence et al.
ENDOCRINOLOGY AND METABOLISM CLINICS OF NORTH AMERICA (2011)
Prognostic Validity of a Novel American Joint Committee on Cancer Staging Classification for Pancreatic Neuroendocrine Tumors
Jonathan R. Strosberg et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Everolimus plus octreotide long-acting repeatable for the treatment of advanced neuroendocrine tumours associated with carcinoid syndrome (RADIANT-2): a randomised, placebo-controlled, phase 3 study
Marianne E. Pavel et al.
LANCET (2011)
Sunitinib Malate for the Treatment of Pancreatic Neuroendocrine Tumors.
Eric Raymond et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
Everolimus for Advanced Pancreatic Neuroendocrine Tumors.
James C. Yao et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
DAXX/ATRX, MEN1, and mTOR Pathway Genes Are Frequently Altered in Pancreatic Neuroendocrine Tumors
Yuchen Jiao et al.
SCIENCE (2011)
18F-Fluorodeoxyglucose Positron Emission Tomography Predicts Survival of Patients with Neuroendocrine Tumors
Tina Binderup et al.
CLINICAL CANCER RESEARCH (2010)
Gastroenteropancreatic neuroendocrine tumours: the current incidence and staging based on the WHO and European Neuroendocrine Tumour Society classification: an analysis based on prospectively collected parameters
Martin B. Niederle et al.
ENDOCRINE-RELATED CANCER (2010)
NANETS Treatment Guidelines Well-Differentiated Neuroendocrine Tumors of the Stomach and Pancreas
Matthew H. Kulke et al.
PANCREAS (2010)
The NANETS Consensus Guideline for the Diagnosis and Management of Neuroendocrine Tumors Well-Differentiated Neuroendocrine Tumors of the Jejunum, Ileum, Appendix, and Cecum
J. Philip Boudreaux et al.
PANCREAS (2010)
The NANETS Consensus Guidelines for the Diagnosis and Management of Poorly Differentiated (High-Grade) Extrapulmonary Neuroendocrine Carcinomas
Jonathan R. Strosberg et al.
PANCREAS (2010)
Gemcitabine and Oxaliplatin Combination Chemotherapy for Metastatic Well-differentiated Neuroendocrine Carcinomas A Single-Center Experience
Philippe A. Cassier et al.
CANCER (2009)
Placebo-Controlled, Double-Blind, Prospective, Randomized Study on the Effect of Octreotide LAR in the Control of Tumor Growth in Patients With Metastatic Neuroendocrine Midgut Tumors: A Report From the PROMID Study Group
Anja Rinke et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Pancreatic neuroendocrine tumors (PNETs): incidence, prognosis and recent trend toward improved survival
T. R. Halfdanarson et al.
ANNALS OF ONCOLOGY (2008)
One hundred years after Carcinoid: Epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States
James C. Yao et al.
JOURNAL OF CLINICAL ONCOLOGY (2008)
Temozolomide as monotherapy is effective in treatment of advanced malignant neuroendocrine tumors
Sara Ekeblad et al.
CLINICAL CANCER RESEARCH (2007)
Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours?
Emilio Bajetta et al.
CANCER CHEMOTHERAPY AND PHARMACOLOGY (2007)
Gastroenteropancreatic endocrine tumors: clinical characterization before therapy
Eric Baudin
NATURE CLINICAL PRACTICE ENDOCRINOLOGY & METABOLISM (2007)
Efficacy of a chemotherapy combination for the treatment of metastatic neuroendocrine tumours
E Bajetta et al.
ANNALS OF ONCOLOGY (2002)
Share Paper
